Abstract
Renal transplantation is the method of choice for patients with end stage kidney failure. But transplanted allograft could be affected by viral and bacterial infections and immune rejections. The standard test for the diagnosis of acute pathologies in kidney transplants is the renal biopsy. However, noninvasive tests would be desirable. Various methods using different techniques have been developed by the transplantation community. But these methods expect improvements. We present here a cost-effective method based on estimating donor-specific DNA fraction in recipient urine based on sequencing of recipient urine DNA only. We hypothesized that in the no-pathology stage, the largest tissue types present in recipient urine are donor kidney cells and in case of rejection, a larger number of recipient immune cells would be observed. Extensive in-silico simulation was used to tune the sequencing parameters: number of variants and depth of coverage. Sequencing of DNA mixture from 2 healthy individuals showed the method high prediction accuracy (maximum error < 0.04). We then demonstrated the insignificant impact of familial relationship and ethnicity using an in-house and public database. Lastly, we performed recipient deep urine DNA sequencing in 32 samples representing two pathology groups: acute rejection (AR, 12 samples) and acute tubular injury (ATI, 11 samples) and 9 samples with no pathology. We found a significant association between the donor-specific DNA fraction in the two pathology groups compared to no pathology (P = 0.0064 for AR and P = 0.026 for ATI). We conclude that deep DNA sequencing of recipient urine offers a noninvasive means of diagnosing and prognosticating acute pathologies in the human kidney allograft.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AB QNRF grant NPRP12S-0227-190173. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. TM NIH grant K08DK087824. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. MS NIH MERIT Award, R37AI051652. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Kidney transplant recipients reported herein provided written informed consent to participate in Weill Cornell Medicine IRB approved study protocol entitled Use of urine PCR to evaluate renal allograft status and the informed consent was obtained before collection of urine specimen and inclusion in the study protocol. The participants provided consent for storage of biospecimens and use of these specimens in future research. The clinical and research activities that we report here are consistent with the principles of the Declaration of Istanbul on Organ Trafficking and Transplant Tourism and the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data cannot be shared publicly because of ethical restrictions. Data are available from the Weill Cornell Medicine Institutional Data Access / Ethics Committee (contact via irb{at}med.cornell.edu) for researchers who meet the criteria for access to confidential data.
